NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells

Cells. 2021 Jun 30;10(7):1647. doi: 10.3390/cells10071647.

Abstract

Development of resistance to therapy in ovarian cancer is a major hinderance for therapeutic efficacy; however, new mechanisms of the resistance remain to be elucidated. NADPH oxidase 4 (NOX4) is responsible for higher NADPH activity to increase reactive oxygen species (ROS) production. In this study, we showed that higher levels of NOX4 were detected in a large portion of human ovarian cancer samples. To understand the molecular mechanism of the NOX4 upregulation, we showed that NOX4 expression was induced by HIF-1α and growth factor such as IGF-1. Furthermore, our results indicated that NOX4 played a pivotal role in chemotherapy and radiotherapy resistance in ovarian cancer cells. We also demonstrated that NOX4 knockdown increased sensitivity of targeted therapy and radiotherapy through decreased expression of HER3 (ERBB3) and NF-κB p65. Taken together, we identified a new HIF-1α/NOX4 signal pathway which induced drug and radiation resistance in ovarian cancer. The finding may provide a new option to overcome the therapeutic resistance of ovarian cancer in the future.

Keywords: HER3; HIF-1α; NOX4; ovarian cancer; therapeutic resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Afatinib / pharmacology
  • Alternative Splicing / genetics
  • Carcinogenesis / metabolism
  • Carcinogenesis / pathology
  • Cell Line, Tumor
  • Down-Regulation / drug effects
  • Drug Resistance, Neoplasm*
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Knockdown Techniques
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Insulin-Like Growth Factor I / pharmacology
  • Models, Biological
  • NADPH Oxidase 4 / genetics
  • NADPH Oxidase 4 / metabolism*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology
  • Progression-Free Survival
  • Receptor, ErbB-3 / metabolism*
  • Signal Transduction*
  • Transcription Factor RelA / metabolism
  • Transcription, Genetic / drug effects
  • Trastuzumab / pharmacology

Substances

  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Transcription Factor RelA
  • Afatinib
  • Insulin-Like Growth Factor I
  • NADPH Oxidase 4
  • ERBB3 protein, human
  • Receptor, ErbB-3
  • Trastuzumab